Chemoprevention of prostate cancer with finasteride

Edith D. Canby-Hagino, Timothy C. Brandt, Javier Hernandez, Ian M. Thompson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Prostate cancer is a significant cause of disease and death, making it an attractive target for chemoprevention. The association between lifetime exposure to dihydrotestosterone and risk of developing prostate cancer suggests that chemoprevention is possible with 5α-reductase inhibition. The recently completed Prostate Cancer Prevention Trial indicates that chemoprevention is possible with the 5α-reductase inhibitor finasteride. Development of a costeffective chemoprevention strategy for prostate cancer is evolving, and is expected to have significant positive economic and public health benefits.

Original languageEnglish (US)
Pages (from-to)899-905
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume7
Issue number7
DOIs
StatePublished - May 2006

Fingerprint

Finasteride
Chemoprevention
Prostatic Neoplasms
Oxidoreductases
Dihydrotestosterone
Insurance Benefits
Cause of Death
Public Health
Economics

Keywords

  • 5α-reductase
  • Chemoprevention
  • Finasteride
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Canby-Hagino, E. D., Brandt, T. C., Hernandez, J., & Thompson, I. M. (2006). Chemoprevention of prostate cancer with finasteride. Expert Opinion on Pharmacotherapy, 7(7), 899-905. https://doi.org/10.1517/14656566.7.7.899

Chemoprevention of prostate cancer with finasteride. / Canby-Hagino, Edith D.; Brandt, Timothy C.; Hernandez, Javier; Thompson, Ian M.

In: Expert Opinion on Pharmacotherapy, Vol. 7, No. 7, 05.2006, p. 899-905.

Research output: Contribution to journalArticle

Canby-Hagino, ED, Brandt, TC, Hernandez, J & Thompson, IM 2006, 'Chemoprevention of prostate cancer with finasteride', Expert Opinion on Pharmacotherapy, vol. 7, no. 7, pp. 899-905. https://doi.org/10.1517/14656566.7.7.899
Canby-Hagino, Edith D. ; Brandt, Timothy C. ; Hernandez, Javier ; Thompson, Ian M. / Chemoprevention of prostate cancer with finasteride. In: Expert Opinion on Pharmacotherapy. 2006 ; Vol. 7, No. 7. pp. 899-905.
@article{86b92a9dde7742edb1d63b96b09ec391,
title = "Chemoprevention of prostate cancer with finasteride",
abstract = "Prostate cancer is a significant cause of disease and death, making it an attractive target for chemoprevention. The association between lifetime exposure to dihydrotestosterone and risk of developing prostate cancer suggests that chemoprevention is possible with 5α-reductase inhibition. The recently completed Prostate Cancer Prevention Trial indicates that chemoprevention is possible with the 5α-reductase inhibitor finasteride. Development of a costeffective chemoprevention strategy for prostate cancer is evolving, and is expected to have significant positive economic and public health benefits.",
keywords = "5α-reductase, Chemoprevention, Finasteride, Prostate cancer",
author = "Canby-Hagino, {Edith D.} and Brandt, {Timothy C.} and Javier Hernandez and Thompson, {Ian M.}",
year = "2006",
month = "5",
doi = "10.1517/14656566.7.7.899",
language = "English (US)",
volume = "7",
pages = "899--905",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Chemoprevention of prostate cancer with finasteride

AU - Canby-Hagino, Edith D.

AU - Brandt, Timothy C.

AU - Hernandez, Javier

AU - Thompson, Ian M.

PY - 2006/5

Y1 - 2006/5

N2 - Prostate cancer is a significant cause of disease and death, making it an attractive target for chemoprevention. The association between lifetime exposure to dihydrotestosterone and risk of developing prostate cancer suggests that chemoprevention is possible with 5α-reductase inhibition. The recently completed Prostate Cancer Prevention Trial indicates that chemoprevention is possible with the 5α-reductase inhibitor finasteride. Development of a costeffective chemoprevention strategy for prostate cancer is evolving, and is expected to have significant positive economic and public health benefits.

AB - Prostate cancer is a significant cause of disease and death, making it an attractive target for chemoprevention. The association between lifetime exposure to dihydrotestosterone and risk of developing prostate cancer suggests that chemoprevention is possible with 5α-reductase inhibition. The recently completed Prostate Cancer Prevention Trial indicates that chemoprevention is possible with the 5α-reductase inhibitor finasteride. Development of a costeffective chemoprevention strategy for prostate cancer is evolving, and is expected to have significant positive economic and public health benefits.

KW - 5α-reductase

KW - Chemoprevention

KW - Finasteride

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33646594704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646594704&partnerID=8YFLogxK

U2 - 10.1517/14656566.7.7.899

DO - 10.1517/14656566.7.7.899

M3 - Article

C2 - 16634712

AN - SCOPUS:33646594704

VL - 7

SP - 899

EP - 905

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -